Meropenem is a β-lactam antibiotic of the carbapenem subclass that has been shown to inhibit penicillinase-negative, -positive and methicillin-susceptible staphylococci. This compound demonstrates the ability to also affect strains of 11 species of streptococci. Mechanistic studies suggest that Meropenem's antimicrobial activity is based on its high affinity for the majority of penicillin-binding proteins, which are cell wall-synthesizing enzymes. Meropenem is very effective because it resists inactivation by the majority of microbial LACTB (β-lactamases) as well as kidney dehydropeptidase I. Experiments have shown Meropenem to have a low toxicity profile and, in contrast to similar compounds, no central nervous system toxicity.
 

Meropenem is an antibiotic that has a wide range of antibacterial properties and is available for injection to treat a variety of different infections, including meningitis and pneumonia. It is a beta-lactam antibiotic that belongs to the classification of carbapenems.
Meropenem is an anti-infective drug that is suitable for infections caused by single or multiple meropenem-sensitive bacteria in adults and children. Severe infections in the hospital and mixed drugs with G-bacteria-based mixed infections, multi-drug resistant infections, and enzyme-producing infections. Pneumonia includes nosocomial pneumonia, urinary tract infections, gynecological infections (such as endometritis and pelvic inflammatory disease), skin and soft tissue infections, meningitis, and sepsis.